key: cord-0911120-ye3w90yk
authors: Sanchis-Gomar, Fabian; Lavie, Carl J.; Perez-Quilis, Carme; Henry, Brandon M.; Lippi, Giuseppe
title: In Reply - Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers
date: 2020-05-21
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2020.05.003
sha: b80d54b2573d64e9003efae434f0c8347de1b371
doc_id: 911120
cord_uid: ye3w90yk

nan

To the Editor: We thank Dr. Gersh for her interest and comments on our manuscript, as well as for taking the time to express her concerns on this subject. We agree with Dr. Gersh that discontinuation of anti-hypertensives angiotensin-converting enzyme (ACE) inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the management of hypertension (HTN) is unjustified at this moment due to the lack of evidence on negative effects of these drugs in patients with coronavirus disease 2019 (COVID-19). However, in recent weeks, several important articles have been published, shedding new light in reference to the potential interplay of ACEIs and ARBs with COVID-19.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus which causes COVID-19, penetrates the cells primarily through ACE2, its natural receptor at cell surface.

Whether ACEIs and ARB administration would increase ACE2 levels or expression remains mostly speculative, as does whether increased ACE2 expression is beneficial or detrimental in COVID-19. As noted by Dr. Gersh, Diaz argued that as ACE2 levels increase after intravenous infusion of ACEIs and ARBs in animal models, taking ACEIs or ARBs may aggravate the infection severity in COVID-19 patients. 1 However, not all studies conducted in animals clearly shown increased ACE2 levels in response to ACEI/ARB administration. 2 Importantly, investigations analyzing changes in plasma or tissue ACE2 levels in humans are limited. In fact, two studies in patients with atrial fibrillation or coronary heart disease found no differences in plasma ACE2 levels between those taking ACEIs or ARBs versus those not taking these medications. 3, 4 Nonetheless, plasma levels may not reflect tissue ACE2 expression, and vice versa, and this topic requires further investigation.

The role of ACE2 expression in COVID-19 morbidity and mortality is still unknown. As hypertension is a clear risk factor for COVID-19, 5 Dr. Gersh noted that many such patients are likely to be on ACEIs or ARBs, and, as such, these anti-HTN medications may be directly connected with infection severity. However, although a relatively high percentage of COVID-19 patients hospitalized have HTN, the percentage of HTN in adults is similar worldwide, increasing with age. In patients with COVID-19, the odds of disease severity with HTN was found in meta-regression to be associated with advancing age. 5 As Marin has also stated, an epidemiological association based simply on prevalence of HTN and ACEI/ARBs in COVID-19 is inappropriate. 6 Moreover, it has been previously reported that ACE2 expression is reduced in HTN animal models and, historically, HTN has not affect outcomes of other coronavirus infections. 7 Most concerning is the fact that Marin claimed that many patients from South America, Central America and Spain have abruptly interrupted their treatments with ACEIs or ARBs over these hypothetical concerns, which might may be as equally dangerous to the patient as COVID-19 itself. 6 Thankfully, to address these concerns, new data is emerging. Mehra et al. 8 analyzed the factors associated with increased risk of in-hospital death in 8,910 COVID-19 patients included in an observational database of 169 worldwide hospitals. Among those factors, the authors found that ACEIs were independently associated with a significant 67% reduction in mortality in a subgroup with hypertension, whereas ARBs were associated with an insignificant 23% higher mortality. 8 Taking ACEIs or statins were associated with higher rates of survival after hospital discharge, while taking ARBs had no effect. Additionally, there was no increased risk of in-hospital death associated with either ACEIs (2.1% vs. 6.1%; odds ratio, 0.33; 95% CI, 0.20 to 0.54) or ARBs (6.8% vs. 5.7%; odds ratio, 1.23; 95% CI, 0.87 to 1.74). Likewise, Mancia et al. 9 carried out a case-control study involving 6,272 confirmed COVID-19 patients from the Lombardy region of Italy. They compared COVID-19 patients with 30,759 controls matched by age, sex, and municipality of residence. Neither ACEIs , nor ARBs, were associated with increased probability of being infected by SARS-CoV-2 in multivariate logistic-regression analysis. Moreover, no association was observed between these drugs and SARS-CoV-2 infection severity. Reynolds et al. 10 8 data, which suggested more benefits with ACEIs, no differences were observed between patients taking ACEIs and those taking ARBs. These authors concluded that neither ACEIs nor ARBs may be associated with severity or mortality of COVID-19 patients. 8 In a retrospective, multicenter study including 1128 adult COVID-19 Chinese patients with HTN, 188 taking ACEIs/ARBs and 940 without these agents, Zhang et al. 12 reported that unadjusted mortality rate was lower in the ACEIs/ARBs group versus the non-ACEIs/ARBs group (3.7% vs. 9.8%; p=0.01). After adjusting for age, gender, comorbidities, and in-hospital medications, the risk for all-cause mortality was still lower in the ACEIs/ARBs group versus the non-ACEIs/ARBs group (adjusted hazard ratio, 0.42; 95% CI, 0.19-0.92; p=0.03). Their results also demonstrated lower risk of COVID-19 mortality in patients who received ACEIs/ARBs versus those who did not (adjusted hazard ratio, 0.37; 95% CI, 0.15-0.89; P = 0.03) in a propensity score-matched analysis followed by adjusting imbalanced variables in mixed-effect Cox model. Moreover, compared to other anti-HTN drugs, ACEIs/ARBs were associated with lower mortality (adjusted hazard ratio, 0.30; 95%CI, 0.12-0.70; P = 0.01) in . Therefore, what can be reasonably concluded from the recently published large single and multi-center studies from multiple countries, is that there is no significant risk of disease severity or mortality associated with ACEI/ARB, with some even suggesting potential benefits in patient with COIVD-19.

The mechanism behind any potential benefit of ACEI and ARB in COVID-19 is still enigmatic. Differences in inflammatory and immune biomarkers has been reported in COVID-19 patients taking ACEI and ARBs. Meng et al. 13 found a reduced rate of severe COVID-19 disease and lower levels of interleukin-6, increased CD3 and CD8 T-cell in peripheral blood, and decreased peak viral loads compared to those using other anti-HTN medication. Moreover, Yang et al. reported that COVID-19 patients with HTN taking ACEI and ARBs had significantly lower C reactive protein and procalcitonin, as well as decreased rate of critical illness and death. 14 ARBs have been also shown to be effective in treating patients with sepsis, pneumonia and influenza. Moreover, a combination of statin and ARBs appeared to substantially reduce mortality during the recent Ebola outbreak dramatically, 15 similar to the reduction in mortality noted by Mehra et al. 8 with ACEIs/statin therapy in COVID-19.

It has been suggested that higher doses of ARBs may protect COVID-19 patients from acute lung injury (ALI) via two complementary mechanisms: (i) by blocking excessive angiotensin II binding promoting vasoconstriction, inflammation, and oxidative damage; ii) by up-regulating ACE2 and increasing angiotensin 1-7 production. 16 In fact, trials using Losartan to reduce ALI in COVID-19 are currently underway in the United States.

Interestingly, ACEI were reported by Mehra et al. 8 to reduce mortality, while a similar effect

Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

Myocardial infarction increases ACE2 expression in rat and humans

Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling

Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease

Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis

Facts and reflections on COVID-19 and anti-hypertensives drugs

CORONAVIRUS: What are the implications for cardiology?

Cardiovascular disease, drug therapy, and mortality in Covid-19

Renin-angiotensin-aldosterone system blockers and the risk of Covid-19

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study

Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola

Angiotensin-Converting Enzyme 2 and Anti-Hypertensives (Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors) in Coronavirus Disease 2019 (COVID-19)

Hyperinflammation and Derangement of Renin-Angiotensin-Aldosterone System in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis